KABIRU AKERE: Open Payments
NPI 1043659444 · GARLAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$644 in 21 payments from 9 companies in 2025. Trend: 2023 $301 · 2024 $226 · 2025 $644
Food & beverage: $644
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $219 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $142 |
| Corcept Therapeutics | 2 | $141 |
| Soleno Therapeutics, Inc. | 1 | $30 |
| Lilly USA, LLC | 2 | $30 |
| Phadia US Inc. | 1 | $26 |
| Dexcom, Inc. | 1 | $24 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
| Amgen Inc. | 1 | $15 |
Products named: Ozempic, JARDIANCE, Korlym, VYKAT XR, ImmunoCAP, Dexcom G6 Transmitter, Rybelsus, Wegovy.
Industry payments across TX — which companies pay providers there.
